Skip to main content

Advertisement

Table 1 Characteristics of patients with 12 (M12) or 24 (M24) months ART experience

From: Virological outcome among HIV-1 infected patients on first-line antiretroviral treatment in semi-rural HIV clinics in Togo

Characteristics M12 M24
Aného (AN) Kpalimé (KP) Atakpamé (AT) Kara (KA) Total Aného (AN) Kouvé (KO) Kpalimé (KP) Atakpamé (AT) Kara (KA) Total
Number of patients (n) 19 14 26 43 102 58 103 37 50 37 285
Women (%) 17 (89.5 %) 13 (92.8 %) 20 (76.9 %) 34 (79.1 %) 84 (82.4 %) 42 (72.4 %) 74 (71.9 %) 26 (70.3 %) 39 (78.0 %) 24 (64.9 %) 205 (71.9 %)
Median age years (IQR) 42 (35–51) 38 (36–49) 35 (33–42) 36 (31–40) 36 (31–42) 40 (35–44) 38 (32–45) 40 (34–46) 36 (30–46) 37 (33–42) 39 (33–45)
WHO stages
 1/2 2/19 (10.5 %) 9/14 (64.3 %) 15/24 (62.5 %) 20/42 (47.6 %) 46/99 (46.4 %) 13/58 (22.4 %) 24/102 (23.5 %) 18/34 (52.9 %) 39/43 (90.7 %) 13/37 (35.1 %) 107/274 (39.1 %)
 3/4 17/19 (89.5 %) 5/14 (35.7 %) 9/24 (37.5 %) 22/42 (52.4 %) 53/99 (53.6 %) 45/58 (77.6 %) 78/102 (76.5 %) 16/34 (47.1 %) 4/43 (9.3 %) 24/37 (64.9 %) 167/274 (60.9 %)
CD4 counts available at baseline (n) 18 (94.7 %) 14 (100 %) 26 (100 %) 43 (100 %) 101 (99.0 %) 56/58 (96.6 %) 103/103 (100 %) 31/37 (83.8 %) 42/50 (84 %) 35/37 (94.6 %) 667/285 (93.7 %)
Median CD4 counts at baseline (IQR) 107 (86–181) 109 (71–235) 197 (111–277) 202 (101–274) 176 (86–261) 134 (110–210) 154 (75–232) 120 (80–158) 201 (167–242) 135 (106–185) 152 (88–219)
First line drugs n (%)
 AZT-3TC-EFV 1 (5.3 %) 1 (3.8 %) 1 (2.3 %) 3 (2.9 %) 1 (1.7 %) 6 (5.8 %) 2 (5.4 %) 10 (20.0 %) 3 (8.1 %) 23 (8.1 %)
 AZT-3TC-NVP 1 (5.3 %)   10 (23.3 %) 11 (10.8 %) 7 (12.1 %) 6 (12.0 %) 13 (4.6 %)
 AZT-3TC-NVP/EFV 2 (1.9 %) 2 (0.7 %)
 D4T-3TC-NVP 1 (5.3 %) 5 (35.7 %) 7 (26.9 %) 2 (4.7 %) 15 (14.7 %) 4 (6.9 %) 3 (2.9 %) 1 (2.0 %) 1 (2.7 %) 9 (3.2 %)
 D4T/AZT-3TC-NVP 16 (84.2 %) 7 (20.0) 15 (57.7 %) 28 (65.1 %) 66 (64.7 %) 43 (75.8 %) 86 (83.5 %) 32 (86.5 %) 32 (64.0 %) 33 (89.2 %) 226 (79.3 %)
 D4T/AZT-3TC-NVP/EFV 2 (10.0 %) 1 (3.8 %)   3 (2.9 %) 3 (5.2 %) 1 (0.98 %) 3 (8.1 %) 7 (2.5 %)
 D4T/AZT/TDF-3TC-NVP/EFV 1 (3.8 %) 1 (2.3 %) 2 (1.9 %) 2 (1.9 %) 2 (0.7 %)
 TDF-3TC-AZT 1 (0.98 %) 1 (0.3 %)
 TDF-3TC-NVP 1 (3.8 %) 1 (0.99 %)
 AZT/TDF-3TC-NVP/EFV 1 (2.3 %) 1 (0.99 %)
 D4T/AZT/TDF-3TC-EFV 1 (0.98 %) 1 (0.3 %)
 AZT/TDF-3TC-EFV 1 (0.98 %) 1 (0.3 %)
 VL >1000 copies/ml n (%) 6/19 (31.6 %) 3/14 (23.1 %) 5/26 (19.2 %) 6/43 (13.9 %) 20/102 (19.6 %) 13/58 (22.4 %) 14/103 (13.6 %) 11/37 (29.7 %) 9/50 (18.0 %) 3/37 (8.1 %) 50/285 (17.5 %)
 Obtained pol sequences (n/n tested) 6/6 3/3 5/5 6/6 20/20 12/13 14/14 10/11 8/9 3/3 47/50
 Frequency of drug resistant HIV (n/n tested) 6/6 3/3 5/5 6/6 20/20 12/12 13/14 10/10 7/8 3/3 45/47
 NRTI only 0 0 0 0 0/20 0 0 1 1 0 2
 NNRTI only 0 0 0 0 0/20 3 1 0 0 0 4
 NRTI + NNRTI 6 3 5 6 20/20 9 12 9 6 3 39
 Global drug resistance n (%) 6/19 (31.6 %) 3/14 (23.1 %) 5/26 (19.2 %) 6/43 (13.9 %) 20/102 (19.6 %) 12/58 (20.7 %) 13/103 (12.6 %) 10/37 (27.0 %) 7/50 (14.0 %) 3/37 (8.1 %) 45/285 (15.8 %)
 Resistance to 2 drugs of first line ART 4 3 3 2 12/20 2 6 5 2 0 15/45
 Resistance to 3 drugs of first line ART 2 0 2 4 8/20 7 6 5 4 3 25/45
Cross-resistance to second line NNRTI
 ETV 1 0 1 1 3/20 3 3 3 1 1 11/45
 RPV 3 1 3 6 13/20 9 8 6 5 3 31/45
Cross-resistance to other NRTIs
 ABC 2(I) 0 2 1 3/20 2 1 3 1 2 9/45
 DDI 0 0 1 0 1/20 2 0 0 0 0 2/45
 TDF 0 0 1 0 1/20 1 1 0 0 0 2/45